Researchers have identified a key genetic vulnerability in aggressive compact cell neuroendocrine cancers, offering a potential new avenue for treatment development. The discovery, stemming from a study at UCLA, centers on the E2F3 protein and its unexpected role in the survival of these cancers when a crucial tumor suppressor gene, RB, is lost. This finding could lead to faster development of therapies, potentially by repurposing drugs already approved for other conditions. Understanding the genetic drivers of these cancers is critical, as they are known for their rapid growth, tendency to spread, and resistance to conventional treatments.
Small cell neuroendocrine cancers are a relatively rare but particularly dangerous group of malignancies that can occur in various parts of the body, including the lungs, prostate, and ovaries. These cancers are often diagnosed at a later stage, making treatment more challenging. The loss of the RB gene – a gene that normally controls cell division – is a hallmark of these tumors. Still, the UCLA research reveals that when RB is lost, cancer cells become unusually reliant on the E2F3 protein to continue growing and dividing. This dependency presents a potential therapeutic target. The study, published in Proceedings of the National Academy of Sciences, details how manipulating E2F3 levels can disrupt cancer cell growth.
Uncovering a Hidden Dependency
The research team, led by Owen N. Witte, presidential chair in developmental immunology and a member of the UCLA Health Jonsson Cancer Center, used advanced genetic techniques to pinpoint E2F3’s role. They developed laboratory models mimicking human small cell prostate cancer by genetically altering human prostate cells. Using CRISPR gene-editing technology, they systematically tested thousands of genes to determine which were essential for the cancer cells’ survival. The results consistently showed a strong dependence on E2F3 across various small cell neuroendocrine cancer types, according to the study.
“Discovering a vulnerability like this opens the door to thinking about entirely new treatment strategies,” Witte said in a UCLA Health news release. “That’s especially important because there has not been a major change in how we treat these cancers for decades.” The concept of targeting this dependency falls under a principle known as “synthetic lethality.” This occurs when the loss of two genes together leads to cell death, even as the loss of either gene alone does not. In this case, the loss of RB combined with targeting E2F3 proved fatal to the cancer cells in laboratory settings.
Repurposing Existing Drugs for Faster Impact
Currently, We find no drugs specifically designed to block the activity of E2F3. However, the UCLA team explored alternative strategies to reduce E2F3 levels. They found that inhibiting the DHODH enzyme – an enzyme involved in the production of DNA building blocks – effectively lowered E2F3 levels and slowed tumor growth. Importantly, several DHODH inhibitors are already approved by the Food and Drug Administration (FDA) for treating autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Leflunomide and teriflunomide are two such examples, according to the FDA’s drug database.
This finding is particularly encouraging because it suggests a faster path to clinical application. Repurposing existing drugs often bypasses the lengthy and expensive process of developing new medications. “What’s exciting is that our findings open the door to applying existing drugs in a new way,” explained Evan Abt, assistant professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA. “By understanding how these cancers depend on E2F3, we can start to think about strategies that might work much more quickly in patients.”
What In other words for Patients
While these findings are promising, it’s crucial to remember that the research is still in its early stages. The experiments were conducted in laboratory settings, and further studies are needed to determine the safety and effectiveness of this approach in humans. Clinical trials will be necessary to evaluate whether DHODH inhibitors, or other strategies to target E2F3, can successfully treat small cell neuroendocrine cancers in patients.
The potential impact extends beyond lung and prostate cancers. The study found that the E2F3 dependency was present in small cell neuroendocrine tumors originating from various organs, suggesting a broad applicability of these findings. This research offers a glimmer of hope for individuals diagnosed with these aggressive cancers, which have historically had limited treatment options. The identification of E2F3 as a critical vulnerability provides a new target for drug development and a potential pathway to improved outcomes.
Researchers are now focused on conducting preclinical studies to further refine their understanding of the E2F3 pathway and identify the most effective strategies for targeting it. The next step will involve translating these findings into clinical trials, which are expected to begin within the next few years, according to UCLA Health officials. The team is also exploring potential biomarkers that could help identify patients who are most likely to benefit from this approach.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you or a loved one been affected by small cell neuroendocrine cancer? Share your thoughts and experiences in the comments below. Please also share this article with anyone who might locate this information helpful.
